ES2155099T3 - Animales transgenicos que albergan alelos app que presentan una mutacion sueca. - Google Patents

Animales transgenicos que albergan alelos app que presentan una mutacion sueca.

Info

Publication number
ES2155099T3
ES2155099T3 ES94931891T ES94931891T ES2155099T3 ES 2155099 T3 ES2155099 T3 ES 2155099T3 ES 94931891 T ES94931891 T ES 94931891T ES 94931891 T ES94931891 T ES 94931891T ES 2155099 T3 ES2155099 T3 ES 2155099T3
Authority
ES
Spain
Prior art keywords
alelos
present
transgenic animals
swedish mutation
host app
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94931891T
Other languages
English (en)
Inventor
Lisa C Mcconlogue
Jun Zhoa
Sinha Sukanto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elan Pharmaceuticals LLC
Eli Lilly and Co
Original Assignee
Elan Pharmaceuticals LLC
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26841313&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2155099(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/143,697 external-priority patent/US5604102A/en
Application filed by Elan Pharmaceuticals LLC, Eli Lilly and Co filed Critical Elan Pharmaceuticals LLC
Application granted granted Critical
Publication of ES2155099T3 publication Critical patent/ES2155099T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Humanized animals, e.g. knockin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0312—Animal model for Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0318—Animal model for neurodegenerative disease, e.g. non- Alzheimer's
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0356—Animal model for processes and diseases of the central nervous system, e.g. stress, learning, schizophrenia, pain, epilepsy
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0393—Animal model comprising a reporter system for screening tests
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Abstract

LA INVENCION PROPORCIONA ANIMALES NO-HUMANOS TRANGENICOS Y CELULAS MAMIFERAS NO HUMANAS TRANSGENICAS QUE ALBERGAN UNA CODIFICACION TRANSGENICA DE UN POLIPEPTIDO APP QUE COMPRENDE LA MUTACION SWEDISH.
ES94931891T 1993-10-27 1994-10-18 Animales transgenicos que albergan alelos app que presentan una mutacion sueca. Expired - Lifetime ES2155099T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/143,697 US5604102A (en) 1992-04-15 1993-10-27 Methods of screening for β-amyloid peptide production inhibitors
US08/148,211 US5612486A (en) 1993-10-27 1993-11-01 Transgenic animals harboring APP allele having swedish mutation

Publications (1)

Publication Number Publication Date
ES2155099T3 true ES2155099T3 (es) 2001-05-01

Family

ID=26841313

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94931891T Expired - Lifetime ES2155099T3 (es) 1993-10-27 1994-10-18 Animales transgenicos que albergan alelos app que presentan una mutacion sueca.

Country Status (12)

Country Link
US (5) US5850003A (es)
EP (2) EP1001019A1 (es)
JP (3) JPH09507746A (es)
AT (1) ATE198622T1 (es)
AU (1) AU702293B2 (es)
CA (1) CA2174429C (es)
DE (2) DE69426571T2 (es)
DK (1) DK0730643T3 (es)
ES (1) ES2155099T3 (es)
GR (1) GR3035564T3 (es)
PT (1) PT730643E (es)
WO (1) WO1995011968A1 (es)

Families Citing this family (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5586226A (en) * 1990-05-16 1996-12-17 Canon Kabushiki Kaisha Control method and device for a unicolor printer
ES2204899T3 (es) * 1992-01-07 2004-05-01 Elan Pharmaceuticals, Inc. Modelos de animales transgenicos para la enfermedad de alzheimer.
US6610493B1 (en) * 1993-06-17 2003-08-26 Brigham And Women's Hospital Screening compounds for the ability to alter the production of amyloid-β peptide
DK0730643T3 (da) 1993-10-27 2001-05-14 Elan Pharm Inc Transgene dyr, som huser APP-allel med svensk mutation
CA2182311A1 (en) 1994-01-27 1995-08-03 Karen Hsiao Transgenic non-human mammals with progressive neurologic disease
US5877399A (en) 1994-01-27 1999-03-02 Johns Hopkins University Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease
US5777194A (en) * 1995-04-26 1998-07-07 Cephalon, Inc. Gene-targeted mice with humanized Aβ sequence and Swedish FAD mutation
AU6264996A (en) * 1995-06-07 1996-12-30 Athena Neurosciences, Inc. Method for identifying alzheimer's disease therapeutics usin g transgenic animal models
WO1996040896A1 (en) * 1995-06-07 1996-12-19 Athena Neurosciences, Inc. Method for identifying alzheimer's disease therapeutics using transgenic animal models
US6717031B2 (en) 1995-06-07 2004-04-06 Kate Dora Games Method for selecting a transgenic mouse model of alzheimer's disease
US20010016951A1 (en) 1996-07-24 2001-08-23 Bernd Sommer Transgenic animal model for alzheimer disease
PT920495E (pt) * 1996-07-24 2008-08-18 Novartis Pharma Gmbh Modelo animal transgénico para doença de alzheimer
WO1999009150A1 (en) * 1996-08-15 1999-02-25 Bayer Corporation Method of introducing modifications into a gene
US5898094A (en) * 1996-10-21 1999-04-27 University Of South Florida Transgenic mice expressing APPK670N,M671L and a mutant presenilin transgenes
EP0948612A2 (en) * 1997-01-03 1999-10-13 University Technology Corporation Beta-amyloid toxicity
WO1998046726A1 (en) * 1997-04-15 1998-10-22 Temple University - Of The Commonwealth System Of Higher Education A-myb NULL MUTANT TRANSGENIC ANIMALS AND USES THEREOF
US6284944B1 (en) * 1997-08-29 2001-09-04 Cephalon, Inc, Gene-targeted non-human mammal with a human fad presenilin mutation and generational offspring
US6699671B1 (en) * 1998-09-24 2004-03-02 Pharmacia & Upjohn Company Alzheimer's disease secretase, APP substrates therefor, and uses therefor
US6844148B1 (en) 1998-09-24 2005-01-18 Pharmacia & Upjohn Company Alzheimer's disease secretase, APP substrates therefor, and uses therefor
KR20070013361A (ko) * 1998-09-24 2007-01-30 파마시아 앤드 업존 캄파니 엘엘씨 알츠하이머병 세크레타제
US20040234976A1 (en) * 1998-09-24 2004-11-25 Gurney Mark E. Alzheimer's disease secretase, app substrates therefor, and uses therefor
US7115410B1 (en) * 1999-02-10 2006-10-03 Elan Pharmaceuticals, Inc. β-secretase enzyme compositions and methods
US7456007B1 (en) 1998-12-31 2008-11-25 Elan Pharmaceuticals, Inc. β-secretase enzyme compositions and methods
EP1165609A2 (en) 1999-02-10 2002-01-02 Elan Pharmaceuticals, Inc. Human beta-secretase enzyme, inhibitors and their compositions and uses
EP1063298A3 (en) * 1999-06-04 2001-03-28 Glaxo Group Limited Transgenic Animal Model for Alzheimer Disease
AU5890400A (en) * 1999-06-24 2001-01-09 Baylor College Of Medicine System and method to detect compounds and mutations that upregulate and downregulate expression of nucleotide sequences
US20090162883A1 (en) * 1999-09-23 2009-06-25 Pharmacia & Upjohn Company Alzheimer's Disease Secretase, APP Substrates Thereof, and Uses Thereof
US7514408B1 (en) 1999-12-02 2009-04-07 Elan Pharmaceuticals, Inc. β-secretase enzyme compositions and methods
US6992081B2 (en) 2000-03-23 2006-01-31 Elan Pharmaceuticals, Inc. Compounds to treat Alzheimer's disease
EP1265849B1 (en) * 2000-03-23 2006-10-25 Elan Pharmaceuticals, Inc. Compounds and methods to treat alzheimer's disease
US7371920B2 (en) * 2000-06-20 2008-05-13 The Governing Council Of The University Of Toronto Transgenic mouse model of neurodegenerative disorders
DE60144164D1 (de) 2000-06-20 2011-04-14 Univ Toronto Transgenes Tiermodel für neurodegenerative Krankheiten
US6686449B2 (en) 2000-06-30 2004-02-03 Pharmacia & Upjohn Company Mutant presenilin 1 polypeptides
MXPA02012560A (es) 2000-06-30 2003-05-14 Elan Pharm Inc Compuestos para tratar la enfermedad de alzheimer.
EP1666452A2 (en) 2000-06-30 2006-06-07 Elan Pharmaceuticals, Inc. Compounds to treat Alzheimer's disease
US6846813B2 (en) * 2000-06-30 2005-01-25 Pharmacia & Upjohn Company Compounds to treat alzheimer's disease
PE20020276A1 (es) 2000-06-30 2002-04-06 Elan Pharm Inc COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER
US20030096864A1 (en) * 2000-06-30 2003-05-22 Fang Lawrence Y. Compounds to treat alzheimer's disease
JP5362164B2 (ja) 2000-07-07 2013-12-11 バイオアークティック ニューロサイエンス アーベー アルツハイマー病の予防及び治療
EP1351969A4 (en) * 2000-12-13 2006-04-05 Immunex Corp PROCESS RELATING TO THE PRODUCTION OF IMMORTAL DENDRITIC CELL LINES
MXPA03011046A (es) * 2001-06-01 2004-06-25 Elan Pharm Inc Hidroxialquilaminas.
AU2002315131A1 (en) 2001-06-13 2002-12-23 Elan Pharmaceuticals, Inc. Aminediols as agents for the treatment of alzheimer's disease
WO2003002122A1 (en) * 2001-06-27 2003-01-09 Elan Pharmaceuticals, Inc. Beta-hydroxyamine derivatives useful in treatment of alzheimer's disease
US20070213407A1 (en) * 2001-06-29 2007-09-13 Elan Pharmaceuticals And Pharmacia & Upjohn Company Llc Compounds to treat Alzheimer's disease
MXPA04000338A (es) * 2001-07-10 2004-07-23 Upjohn Co Diamindioles para tratamiento de enfermedad de alzheimer.
US7053109B2 (en) * 2001-07-10 2006-05-30 Pharmacia & Upjohn Company Aminediols for the treatment of Alzheimer's disease
US7244755B2 (en) 2001-10-04 2007-07-17 Pharmacia & Upjohn Company Hydroxypropylamines
BR0214035A (pt) * 2001-11-08 2005-04-26 Elan Pharm Inc Composto
KR100462180B1 (ko) * 2001-11-20 2004-12-16 (주) 디지탈바이오텍 알츠하이머병 병인 유전자로 형질전환된 동물 및 그 제조방법
JP4343695B2 (ja) * 2001-12-20 2009-10-14 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア アルツハイマー病のトリプル・トランスジェニックマウス・モデル
US20040016008A1 (en) * 2002-01-07 2004-01-22 Brimijoin William Stephen Hybrid transgenic mouse with accelerated onsent of Alzheimer type amyloid plaques in brain
US20030199003A1 (en) * 2002-02-27 2003-10-23 Stratman Nancy C. High-level production of amyloid-beta peptides from IMR-32 cells
US7262208B2 (en) * 2002-04-30 2007-08-28 Elan Pharmaceuticals, Inc. Hydroxypropyl amides for the treatment of Alzheimer's disease
JP2004000060A (ja) * 2002-05-31 2004-01-08 Otsuka Pharmaceut Co Ltd アミロイドβ産生に影響を与える化合物のスクリーニング方法
UY27967A1 (es) * 2002-09-10 2004-05-31 Pfizer Acetil 2-hindroxi-1,3-diaminoalcanos
EP1565428A1 (en) * 2002-11-27 2005-08-24 Elan Pharmaceuticals, Inc. Substituted ureas and carbamates
MXPA05011150A (es) 2003-04-21 2005-12-14 Elan Pharm Inc 2-hidroxi-3-diaminoalcanos de benzamida.
PE20050420A1 (es) * 2003-04-21 2005-06-13 Elan Pharm Inc Fenacilo 2-hidroxi-3-diaminoalcanos
CA2525547C (en) * 2003-05-14 2012-07-03 Torreypines Therapeutics, Inc. Compounds and uses thereof in modulating amyloid beta
US20060014790A1 (en) * 2004-01-21 2006-01-19 Varghese John Methods of treatment of amyloidosis using spirocyclohexane aspartyl-protease inhibitors
CA2558034A1 (en) * 2004-03-09 2005-09-22 Elan Pharmaceuticals, Inc. Substituted hydroxyethylamine aspartyl protease inhibitors
JP2007528404A (ja) 2004-03-09 2007-10-11 エラン ファーマシューティカルズ，インコーポレイテッド 置換された尿素およびカルバメート、フェナシル−２−ヒドロキシ−３−ジアミノアルカン、ならびにベンズアミド−２−ヒドロキシ−３−ジアミノアルカン系のアスパラギン酸プロテアーゼ阻害薬
US20050239832A1 (en) * 2004-03-09 2005-10-27 Varghese John Methods of treatment of amyloidosis using bi-cyclic aspartyl protease inhibitors
JP2007528402A (ja) * 2004-03-09 2007-10-11 エラン ファーマシューティカルズ，インコーポレイテッド 置換ヒドロキシエチルアミン系のアスパラギン酸プロテアーゼ阻害薬
SE0400707D0 (sv) 2004-03-22 2004-03-22 Bioarctic Neuroscience Ab Transgenic animal model
KR100584914B1 (ko) * 2004-03-30 2006-05-30 주식회사 뉴로테크 돌연변이 ａｐｐ를 발현하는 알츠하이머병 유발 형질전환마우스
US7544855B2 (en) * 2004-04-23 2009-06-09 Buck Institute Transgenic mouse whose genome comprises an APP having a mutation at amino acid 664
WO2005110422A2 (en) * 2004-05-19 2005-11-24 Boehringer Ingelheim International Gmbh Treatment of diseases associated with altered level of amyloid beta peptides
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
US7385085B2 (en) * 2004-07-09 2008-06-10 Elan Pharmaceuticals, Inc. Oxime derivative substituted hydroxyethylamine aspartyl protease inhibitors
JP2008505929A (ja) * 2004-07-09 2008-02-28 エラン ファーマシューティカルズ，インコーポレイテッド オキシム誘導体ヒドロキシエチルアミン系のアスパラギン酸プロテアーゼ阻害薬
US8426429B2 (en) * 2004-08-06 2013-04-23 Jansssen Pharmaceutica N.V. 2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE)
US8383637B2 (en) * 2004-08-06 2013-02-26 Jansssen Pharmaceutica N.V. 2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE)
US8436006B2 (en) * 2004-08-06 2013-05-07 Jansssen Pharmaceutica N.V. 2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE)
CA2577392A1 (en) * 2004-08-27 2006-03-09 Elan Pharmaceuticals, Inc. Methods of treatment of amyloidosis using ethanol cyclicamine derivatives aspartyl protease inhibitors
WO2006052691A2 (en) * 2004-11-05 2006-05-18 Wyeth Pet and magnetic resonance for screening alzheimer's disease therapeutics
US20090124993A1 (en) 2005-02-17 2009-05-14 Burkly Linda C Treating neurological disorders
EP1907566A4 (en) * 2005-05-27 2008-12-10 Memory Pharm Corp ALZHEIMER TRANSGENIC MOUSE MODEL VECTORS AND USES THEREOF
EP1746092A1 (en) 2005-07-22 2007-01-24 Exonhit Therapeutics SA Compounds and methods for treatment of amyloid-B-peptide related disorders
US20080293680A1 (en) * 2005-08-03 2008-11-27 Stefan Peters Substituted Ethane-1,2-Diamines for the Treatment of Alzheimer's Disease II
EP1915339A1 (de) * 2005-08-11 2008-04-30 Boehringer Ingelheim International GmbH Inhibitoren der beta-sekretase zur behandlung der alzheimer- erkrankung
US20100168070A1 (en) * 2005-08-11 2010-07-01 Niklas Heine Compounds for the treatment of alzheimer's disease
WO2007017509A1 (de) * 2005-08-11 2007-02-15 Boehringer Ingelheim International Gmbh Verbindungen zur behandlung der alzheimer erkrankung
JP2009504614A (ja) * 2005-08-11 2009-02-05 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング アルツハイマー病の治療用化合物
WO2007047305A1 (en) * 2005-10-12 2007-04-26 Elan Pharmaceuticals, Inc. Methods of treating amyloidosis using cyclopropyl derivative aspartyl protease inhibitors
CA2624904A1 (en) * 2005-10-12 2007-04-26 Elan Pharmaceuticals, Inc. Methods of treating amyloidosis using aryl-cyclopropyl derivative aspartyl protease inhibitors
WO2007092846A2 (en) * 2006-02-06 2007-08-16 Janssen Pharmaceutica N.V. 2-AMINO-3,4-DIHYDRO-QUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF β-SECRETASE (BACE)
US7932261B2 (en) * 2006-02-06 2011-04-26 Janssen Pharmaceutica Nv Macrocycle derivatives useful as inhibitors of β-secretase (BACE)
WO2007092854A2 (en) * 2006-02-06 2007-08-16 Janssen Pharmaceutica N.V. 2-AMINO-QUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF β-SECRETASE (BACE)
MY169492A (en) 2006-03-23 2019-04-15 Bioarctic Neuroscience Ab Improved protofibril selective antibodies and the use thereof
TW200808751A (en) * 2006-04-13 2008-02-16 Astrazeneca Ab New compounds
US20070292895A1 (en) * 2006-05-19 2007-12-20 Xiao-Ping Shi Assays and methods to detect beta-secretase and its activity in body fluids and tissue extracts
TW200815349A (en) 2006-06-22 2008-04-01 Astrazeneca Ab New compounds
EA016568B1 (ru) 2006-10-12 2012-05-30 Беллус Хелс (Интернэшнл) Лимитед Способы, соединения, композиции и носители для доставки 3-амино-1-пропансульфоновой кислоты
IL199534A (en) 2007-01-05 2013-01-31 Univ Zuerich An isolated human antibody capable of detecting a neoepitope in a disease-related protein, a polynucleotide encoding an antibody, a vector containing the polynucleotide, a host cell containing the polynucleotide or vector, a preparation containing the antibody and related methods and uses.
US8022268B2 (en) * 2007-06-11 2011-09-20 The University Of Zurich Transgenic animal model for alzheimer's disease
US8222264B2 (en) 2007-07-06 2012-07-17 Boehringer Ingelheim International Gmbh Substituted amino-quinazolinones, medicaments comprising said compound, their use and their method of manufacture
CA2692604A1 (en) * 2007-07-13 2009-01-22 Elan Pharmaceuticals, Inc. Compositions and methods for identifying substrate specificity of inhibitors of gamma secretase
US20090163594A1 (en) * 2007-10-31 2009-06-25 Elan Pharmaceuticals, Inc. Triple Assay System for Identifying Substrate Selectivity of Gamma Secretase Inhibitors
NZ586831A (en) * 2008-01-28 2012-02-24 Janssen Pharmaceutica Nv 6-substituted-thio-2-amino-quinoline derivatives useful as inhibitors of beta-secretase (bace)
US7786116B2 (en) * 2008-01-29 2010-08-31 Janssen Pharmaceutica N.V. 2-amino-quinoline derivatives useful as inhibitors of β-secretase (BACE)
MX2011004891A (es) * 2008-11-13 2011-10-06 Modgene Llc Modificacion de la carga de beta amiloide en el tejido no cerebral.
US20100125087A1 (en) * 2008-11-14 2010-05-20 Astrazeneca Ab New compounds 575
TW201020244A (en) * 2008-11-14 2010-06-01 Astrazeneca Ab New compounds
US20100125081A1 (en) * 2008-11-14 2010-05-20 Astrazeneca Ab New compounds 574
US20110023152A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genome editing of cognition related genes in animals
JP6250394B2 (ja) 2010-08-19 2017-12-20 バック・インスティテュート・フォー・リサーチ・オン・エイジング 軽度の認知障害（ｍｃｉ）および関連障害の処置方法
MX352749B (es) 2011-11-01 2017-12-06 Modgene Llc Composiciones y metodos para la reduccion de la carga amiloide-beta.
EP2637487B1 (de) 2012-03-05 2014-07-16 STULZ GmbH Klimagerät zur Kühlung von Elektronikgeräten oder Elektronikgeräteschränken mit Blech zur verbesserten Luftführung
ES2667861T3 (es) 2012-03-05 2018-05-14 Stulz Gmbh Aparato climatizador para la refrigeración de aparatos electrónicos o armarios de instrumentos electrónicos con rejilla de soplado
AU2013235422B2 (en) 2012-03-19 2016-12-15 Buck Institute For Research On Aging APP specific BACE inhibitors (ASBIs) and uses thereof
EP3653609B1 (en) 2013-02-12 2024-04-03 Buck Institute for Research on Aging Hydantoins that modulate bace-mediated app processing
JP6717740B2 (ja) * 2013-03-15 2020-07-01 パワーヴィジョン・インコーポレーテッド 眼内レンズの収容および載置装置ならびにその使用方法
WO2016005466A2 (en) 2014-07-10 2016-01-14 Bioarctic Neuroscience Ab IMPROVED Aß PROTOFIBRIL BINDING ANTIBODIES
US20170335324A1 (en) 2014-11-12 2017-11-23 The General Hospital Corporation Methods for treating neurodegenerative diseases
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
US11142505B2 (en) 2015-08-27 2021-10-12 The Regents Of The University Of California Compositions for APP-selective BACE inhibition and uses therefor
US20210214406A1 (en) * 2016-04-14 2021-07-15 Tao Health Life Pharma Co., Ltd. Amylospheroid (aspd)-like structure and pharmaceutical composition
US20190134000A1 (en) 2016-05-12 2019-05-09 Buck Institute For Research On Aging Compounds to promote normal processing of app
IL272773B1 (en) 2017-08-22 2024-02-01 Biogen Ma Inc Pharmaceutical preparations containing anti-amyloid cell antibodies
WO2023246838A1 (en) * 2022-06-22 2023-12-28 Tsinghua University Disease model and use thereof

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
BR8401386A (pt) * 1983-03-30 1984-11-06 Du Pont Conector de filtro
US4492760A (en) 1983-04-19 1985-01-08 The Wistar Institute Of Anatomy And Biology HLA D Typing assay
US4736866B1 (en) 1984-06-22 1988-04-12 Transgenic non-human mammals
JPS6147500A (ja) * 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) * 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) * 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) * 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US4666829A (en) 1985-05-15 1987-05-19 University Of California Polypeptide marker for Alzheimer's disease and its use for diagnosis
JPS62100291A (ja) * 1985-10-28 1987-05-09 Teijin Ltd 遺伝子断片およびプラスミド
DE3689123T2 (de) * 1985-11-01 1994-03-03 Xoma Corp Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung.
US4666682A (en) * 1985-11-25 1987-05-19 James L. Mayer Dispenser for solid and powered detergent
US5547841A (en) 1987-10-08 1996-08-20 The Mclean Hospital Corporation In vitro method for screening for drugs that inhibit production or degradation of human A4-amyloid
US5134062A (en) * 1988-03-22 1992-07-28 Cornell Research Foundation, Inc. Diagnosis of neuronal disorders and screening potential therapeutic agents therefor
AU5525090A (en) 1989-04-14 1990-11-16 Research Foundation For Mental Hygiene, Inc. Monoclonal antibody to amyloid peptide
AU5439790A (en) 1989-04-14 1990-11-16 Research Foundation For Mental Hygiene, Inc. Cerebrovascular amyloid protein-specific monoclonal antibody sv17-6e10
US5234814A (en) * 1989-06-01 1993-08-10 Du Pont Merck Pharmaceutical Company Diagnostic assay for alzheimer's disease
US5221607A (en) 1989-09-18 1993-06-22 Scios Nova Inc. Assays and reagents for amyloid deposition
AU7121191A (en) 1990-02-26 1991-10-10 Albert Einstein College Of Medicine Of Yeshiva University Diagnostic assay for alzheimer's disease
EP0527823A1 (en) * 1990-04-24 1993-02-24 The Regents Of The University Of California Purification, detection and methods of use of protease nexin-2
ES2217250T3 (es) * 1990-06-15 2004-11-01 Scios Inc. Mamifero transgenico, no humano que muestra la patologia de formacion amiloides de la enfermedad de alzheimer.
WO1992000521A1 (en) * 1990-06-29 1992-01-09 Case Western Reserve University Diagnostic and prognostic methods based on soluble derivatives of the beta amyloid protein precursor
US5200339A (en) * 1990-08-17 1993-04-06 Abraham Carmela R Proteases causing abnormal degradation of amyloid β-protein precursor
BE1003316A5 (fr) * 1990-11-27 1992-02-25 Will L F & Cie Sa Anticorps monoclonal utile pour le diagnostic de la maladie d'alzheimer, hybridome secreteur d'un tel anticorps monoclonal et procede pour sa preparation.
AU652997B2 (en) * 1991-01-21 1994-09-15 Elan Pharmaceuticals, Inc. Test and model for alzheimer's disease
GB9116030D0 (en) 1991-07-25 1991-09-11 Ssali Charles L Antiviral compositions
ES2204899T3 (es) 1992-01-07 2004-05-01 Elan Pharmaceuticals, Inc. Modelos de animales transgenicos para la enfermedad de alzheimer.
SE511886C2 (sv) 1992-01-31 1999-12-13 Svedala Arbra Ab Sätt att styra en gyratorisk kross
US5604102A (en) 1992-04-15 1997-02-18 Athena Neurosciences, Inc. Methods of screening for β-amyloid peptide production inhibitors
US5441870A (en) 1992-04-15 1995-08-15 Athena Neurosciences, Inc. Methods for monitoring cellular processing of β-amyloid precursor protein
US5455169A (en) * 1992-06-04 1995-10-03 Alzheimer's Institute Of America, Inc. Nucleic acids for diagnosing and modeling Alzheimer's disease
CA2135313A1 (en) 1992-06-18 1994-01-06 Theodore Choi Methods for producing transgenic non-human animals harboring a yeast artificial chromosome
US5837672A (en) 1992-07-10 1998-11-17 Athena Neurosciences, Inc. Methods and compositions for the detection of soluble β-amyloid peptide
US5766846A (en) 1992-07-10 1998-06-16 Athena Neurosciences Methods of screening for compounds which inhibit soluble β-amyloid peptide production
WO1994001772A1 (en) 1992-07-13 1994-01-20 The Children's Medical Center Corporation SCREEN FOR ALZHEIMER'S DISEASE THERAPEUTICS BASED ON β-AMYLOID PRODUCTION
WO1994010569A1 (en) 1992-10-26 1994-05-11 Schenk Dale B METHODS AND COMPOSITIONS FOR THE DETECTION OF SOLUBLE β-AMYLOID PEPTIDE
US5605811A (en) 1992-10-26 1997-02-25 Athena Neurosciences, Inc. Methods and compositions for monitoring cellular processing of beta-amyloid precursor protein
US5750349A (en) 1993-01-25 1998-05-12 Takeda Chemical Industries Ltd. Antibodies to β-amyloids or their derivatives and use thereof
US5955317A (en) 1993-01-25 1999-09-21 Takeda Chemical Industries, Ltd. Antibodies to β-amyloids or their derivatives and use thereof
WO1994023049A2 (en) * 1993-04-02 1994-10-13 The Johns Hopkins University The introduction and expression of large genomic sequences in transgenic animals
DK0730643T3 (da) * 1993-10-27 2001-05-14 Elan Pharm Inc Transgene dyr, som huser APP-allel med svensk mutation

Also Published As

Publication number Publication date
EP0730643A4 (en) 1996-11-27
CA2174429C (en) 2011-08-30
DE69426571D1 (de) 2001-02-15
US20050022257A1 (en) 2005-01-27
DE1001019T1 (de) 2001-01-11
GR3035564T3 (en) 2001-06-29
DE69426571T2 (de) 2001-08-09
EP0730643B1 (en) 2001-01-10
US20020049988A1 (en) 2002-04-25
US7608749B2 (en) 2009-10-27
US20070199079A1 (en) 2007-08-23
US6245964B1 (en) 2001-06-12
ATE198622T1 (de) 2001-01-15
EP1001019A1 (en) 2000-05-17
JP2006122059A (ja) 2006-05-18
AU8080994A (en) 1995-05-22
US5850003A (en) 1998-12-15
PT730643E (pt) 2001-06-29
EP0730643A1 (en) 1996-09-11
WO1995011968A1 (en) 1995-05-04
JP2007267748A (ja) 2007-10-18
US7179953B2 (en) 2007-02-20
CA2174429A1 (en) 1995-05-04
AU702293B2 (en) 1999-02-18
JPH09507746A (ja) 1997-08-12
US6586656B2 (en) 2003-07-01
DK0730643T3 (da) 2001-05-14

Similar Documents

Publication Publication Date Title
ES2155099T3 (es) Animales transgenicos que albergan alelos app que presentan una mutacion sueca.
DK0748386T3 (da) Frembringelse af fibrinogen i transgene dyr
DE69533583D1 (de) Nicht humane, transgenische säugetiere mit sich entwickelnder neurologischer krankheit
DE69104817T2 (de) Laservorrichtung zur Emission von einmodiger Strahlung mit geringer transversaler Divergenz.
DE69523922T2 (de) Fasergitter stabilisierte laserdiode
DK650489D0 (da) Transgene organismer og celler samt fremgangsmaader til fremstilling deraf
PT692869E (pt) Amplificador de potencia com controlo de nivel de limitador
DE69115566D1 (de) Faksimilegerät mit verbesserter summarischer Bestätigung von Quellennachrichten
DK0545854T3 (da) Forskydningsdornforbindelse
DE3889854D1 (de) Abtaster für einen elektrophotografischen Laserdrucker mit vielfachem Abtastfleck.
FR2563679B1 (fr) Limiteur automatique du courant des faisceaux d'un tube-image
NO922836L (no) Pakkboks for elektrisk kabel
DE69425314T2 (de) Gebäude zur Unterbringung von Tieren
EP0962525A4 (en) PHAGE RELATED TO THE NUCLEAR LOCATION SIGNAL
DE69322369T2 (de) Magnetstruktur mit reflektor
ES2108061T3 (es) Gen quimerico que comprende un promotor-regulador y un gen que codifica una proteina indicadora.
NO933707D0 (no) Laserforenelig ventilasjonsroer
DK0900002T3 (da) H2-M-modificerede transgene dyr
DE3670379D1 (de) Projektionskopiergeraet mit einer verbesserten projektions- und abbildungsspiegelanlage.
KR950005949U (ko) 레이저빔 프린터의 현상기 리프트 장치
DK0910623T3 (da) Trombinreceptormodificerede transgene dyr
DE69104741D1 (de) Kopiergerät mit Bildeditor.
DE59702361D1 (de) Vorrichtung zur ablenkung von lichtstrahlen
DK509184D0 (da) Laser-lyslederkobling
ES1022195Y (es) "proyector autonomo de rayo luminoso de posicionamiento programable"

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 730643

Country of ref document: ES